Lim Jong-hoon, CEO of Hanmi Science, "Defending Group Management Rights... Up to 800 Billion Investment"

Continuation of Current System Until 2027 Regardless of Temporary General Meeting
Adding 'External Growth Drivers' to Mid-to-Long-Term Growth Strategy
"Will Not Stop Efforts for Family Harmony"

Lim Jong-hoon, CEO of Hanmi Science, the holding company of Hanmi Group, stated that he will not lose control of the group’s management and unveiled a mid- to long-term growth strategy for Hanmi Group’s leap forward. Through this, he plans to secure renewed trust from the board of directors and shareholders by 2027.

Hanmi Science is holding a "Hanmi Group Value-Up and Mid-to-Long-Term Growth Strategy Press Conference for Enhancing Corporate Value" at 2 p.m. on the 7th at the Glad Hotel in Yeongdeungpo-gu, Seoul. Photo by Choi Tae-won

Hanmi Science announced this on the 7th at 2 p.m. during a press conference titled "Hanmi Group Value-Up and Mid- to Long-Term Growth Strategy to Enhance Corporate Value" held at the Glad Hotel in Yeongdeungpo-gu, Seoul. It stated that amending the articles of incorporation at the extraordinary shareholders’ meeting scheduled for the 29th is impossible, and even if the board is reorganized with an equal 5-to-5 split, the CEO Lim’s leadership will continue until 2027.

Furthermore, at the regular shareholders’ meeting in March next year, the terms of three directors classified as part of the three-party coalition will expire, and at the shareholders’ meeting in March 2026, the term of Song Young-sook, Chairwoman of Hanmi Group, will also expire, enabling the entry of directors supporting the sibling faction, thereby expanding the holding company’s control.

Hanmi Science announced its '2028 Financial Goals and Investment Scale' at the 'Hanmi Group Value-Up and Mid-to-Long-Term Growth Strategy Press Conference for Enhancing Corporate Value' held at 2 p.m. on the 7th at the Glad Hotel in Yeongdeungpo-gu, Seoul. Photo by Choi Taewon

At the 2027 regular shareholders’ meeting, the terms of CEO Lim and sibling faction directors will expire, but the plan is to gain renewed trust from the board and shareholders based on management capabilities and performance.

To this end, the sibling faction revealed a mid- to long-term growth strategy for Hanmi Group’s leap forward. The growth strategy focuses on adding external growth engines. Considering the increasingly fierce external environment, it is judged that growth is limited by relying solely on internal research and development and capabilities.

The disclosed mid- to long-term growth strategy includes detailed strategic tasks across the group such as ▲expansion of new TAs (therapeutic areas) ▲securing promising external innovative technologies and substances through open innovation ▲diversification of healthcare value chain businesses ▲expansion of pharmaceutical raw material CDMO business ▲strengthening distribution capabilities of Online Pharm.

Hanmi Science estimates that up to 800 billion KRW in investment is required to achieve these strategies. Accordingly, if there are investors who understand the pharmaceutical industry and seek mutual benefits, they are ready to negotiate at any time.

Lim Jong-hoon, CEO of Hanmi Science, is speaking at the 'Hanmi Group Value-Up and Mid-to-Long-Term Growth Strategy Press Conference for Enhancing Corporate Value' held at 2 p.m. on the 7th at the Glad Hotel in Yeongdeungpo-gu, Seoul. Photo by Choi Tae-won

Regarding the fact that the three-party coalition holds the largest share in Hanmi Science’s shareholding structure, it was stated that foundations within the group holding certain shares will urge neutral exercise of voting rights. Currently, the shareholding structure of Hanmi Science is 33.78% by the three-party coalition, 25.6% by the sibling faction, 8.09% by Gahyeon Cultural Foundation and Lim Sung-ki Foundation, and 3.1% by relatives.

In response, the sibling faction stated that they will exert pressure using all available means and methods to ensure that the foundations exercise voting rights neutrally. CEO Lim said, "Fair and neutral decision-making by the foundations, along with continuing group management centered on Hanmi Science as it is, will be the first step to family harmony and mending relationships."

The sibling faction added, "We will strongly maintain control over Hanmi Group’s management centered on Hanmi Science for the next two years while practicing responsible management that earns the trust of employees, the board, and shareholders through Hanmi Group’s mid- to long-term growth strategy. We will also continue efforts to normalize the role of foundations within the group and to foster family harmony."